Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN83,7283,661,50
Msft-0,20
Nokia4,3014,4140,52
IBM-1,22
Mercedes-Benz Group AG50,6650,682,77
PFE1,12
03.07.2025 8:30:02
Indexy online
AD Index online
select
AD Index online
 

  • 02.07.2025 17:25:09
Avacta Grp (London)
Poslední obchod Změna (%) Změna (GBP) Objem obchodů (GBP)
0,3001 -3,16 -0,01 608 170
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 03.07.2025
Popis společnosti
Obecné informace
Název společnostiAvacta Group Plc
TickerAVCT
Kmenové akcie:Ordinary Shares
Kmenové akcie:Ordinary Shares
RICAVCT.L
ISINGB00BYYW9G87
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.12.2024
Počet zaměstnanců k 31.12.2024 151
Akcie v oběhu k 24.04.2025 386 868 205
MěnaGBP
Kontaktní informace
UliceUnit 20, Ash Way
MěstoWETHERBY
PSČLS23 7FA
ZeměUnited Kingdom
Kontatní osoba 
Funkce kontaktní osoby 
Telefon441 904 217 070
Fax448444140453

Business Summary: Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Avacta Group Plc revenues decreased 96% to L113K. Net loss before extraordinary items increased 1% to L29.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Central overheads segment loss increase of 93% to L12.6M, Therapeutics segment loss increase of 20% to L20M.
Odvětvová klasifikace
TRBC2009Advanced Medical Equipment
TRBC2012Bio Therapeutic Drugs
RBSS2004Advanced Medical Equipment
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSIn-Vitro Diagnostic Substance Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS2007In-Vitro Diagnostic Substance Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997InVitro Diagnostic Substance Manufacturing
SICCommercial Physical Research
SICDiagnostic Substances



  • Poslední aktualizace: 03.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Executive DirectorChristina Coughlin5430.04.202420.09.2023
Chief Financial Officer, Company SecretaryBrian Hahn5022.01.202522.01.2025
Chief Scientific OfficerMichelle Morrow-04.11.202404.11.2024
Chief Business Officer - TherapeuticsSimon Bennett-19.12.202319.12.2023